Drugs & Targets FDA issues draft guidance on expanded access to investigational drugs November 04, 2022Vol.48 No.40
Drugs & Targets FDA approves Imjudo in combination with Imfinzi for unresectable hepatocellular carcinoma October 28, 2022Vol.48 No.39
Drugs & Targets FDA denies marketing application for menthol e-cigarettes October 28, 2022Vol.48 No.39
In Brief Nicole Gormley named acting associate director for oncology endpoint development at FDA’s OCE October 21, 2022Vol.48 No.38
Drugs & Targets FDA publishes final guidance on drug development for AML October 21, 2022Vol.48 No.38
Drugs & Targets FDA publishes draft guidance on characterizing, collecting, and reporting immune-mediated adverse reactions October 21, 2022Vol.48 No.38
Drugs & Targets FDA publishes draft guidance on tissue agnostic drug development in oncology October 21, 2022Vol.48 No.38
Clinical Roundup New data show more than 2.5M U.S. youth use e-cigarettes October 07, 2022Vol.48 No.36
Drugs & Targets FDA grants accelerated approval to Lytgobi for cholangiocarcinoma October 07, 2022Vol.48 No.36
